Literature DB >> 20969943

Chinese medicine Tongxinluo modulates vascular endothelial function by inducing eNOS expression via the PI-3K/Akt/HIF-dependent signaling pathway.

Jun Qing Liang1, Kun Wu, Zhen Hua Jia, Chang Liu, Jin Ding, Shan Na Huang, Pei Pei Yin, Xiang Chun Wu, Cong Wei, Yi Ling Wu, Hong Yang Wang.   

Abstract

AIM OF THE STUDY: To investigate the molecular mechanisms whereby the Chinese medicinal compound Tongxinluo improves vascular endothelial function through studying the induction of endothelial nitric oxide synthase (eNOS) and its upstream signaling pathway.
MATERIALS AND METHODS: Hyperhomocysteinemia was induced in Wistar rats by a methionine-rich diet followed by Tongxinluo treatment. The aorta ring was isolated for measuring vascular dilation of aorta and eNOS expression. Human umbilical vein endothelial cells (HUVECs) were transfected with AP-1, NF-κB, HRE or eNOS reporter plasmid followed by Tongxinluo exposure. Expression of the reporter genes was measured by luciferase assay. The level of eNOS was studied by western blot and the nitric oxide content was measured using the nitrate reductase method. HUVECs were also transiently transfected with the dominant negative mutant of HIF-1, PI-3K or Akt to explore the role of HIF and PI-3K/Akt pathway in eNOS induction by Tongxinluo.
RESULTS: Tongxinluo could significantly up-regulate the expression of eNOS in the aortic tissue and improve the endothelium-dependent vasodilation of the aorta ring. Additionally, Tongxinluo at various doses could significantly enhance the expression of HRE and eNOS reporter gene as well as up-regulate the protein level of eNOS. Meanwhile, Tongxinluo caused a dose-dependent increase in the NO content in the supernatant of HUVECs. Suppression of HIF-1 activation by DN-HIF or inhibition of PI-3K/Akt pathway by ΔP85 or DN-Akt both attenuated HRE reporter gene activation and eNOS induction by Tongxinluo.
CONCLUSION: Tongxinluo, a compound Chinese traditional medicine, up-regulates the expression of eNOS via the PI-3K/Akt/HIF-dependent signaling pathway, thus improving the endothelium-dependent vasodilation. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20969943     DOI: 10.1016/j.jep.2010.10.031

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  11 in total

1.  Tongxinluo modulates cytokine secretion by cardiac microvascular endothelial cells in ischemia/reperfusion injury.

Authors:  Hehe Cui; Na Li; Xiangdong Li; Kang Qi; Qing Li; Chen Jin; Tianjie Wang; Lian Duan; Leipei Jiang; Guihao Chen; Zhigang Wang; Cong Wei; Yuejin Yang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

2.  Tongxinluo inhibits neointimal formation by regulating the expression and post-translational modification of KLF5 in macrophages.

Authors:  Wen Jiang; Bin Zheng; Xin-Hua Zhang; Ling-Yan Yue; Chan Liu; Dong Ma; Zhan Yang; Jin-Kun Wen
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Tongxinluo promotes mesenchymal stem cell tube formation in vitro.

Authors:  Xin-Yang Hu; Wen-Xia Wang; Min-Jia Yu; Xian-Bao Liu; Rong-Rong Wu; Feng Gao; Xin Huang; Jiang Cao; Xiao-Jie Xie; Jian-An Wang
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

4.  Tongxinluo (TXL), a Traditional Chinese Medicinal Compound, Improves Endothelial Function After Chronic Hypoxia Both In Vivo and In Vitro.

Authors:  Cui-Ying Zheng; Li-Li Song; Jin-Kun Wen; Li-Min Li; Zong-Wei Guo; Pei-Pei Zhou; Chang Wang; Yong-Hui Li; Dong Ma; Bin Zheng
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

5.  Effects of Chinese Medicine Tong xinluo on Diabetic Nephropathy via Inhibiting TGF- β 1-Induced Epithelial-to-Mesenchymal Transition.

Authors:  Na Zhang; Yanbin Gao; Dawei Zou; Jinyang Wang; Jiaoyang Li; Shengnan Zhou; Zhiyao Zhu; Xuan Zhao; Liping Xu; Haiyan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-17       Impact factor: 2.629

6.  Tongxinluo inhibits cyclooxygenase-2, inducible nitric oxide synthase, hypoxia-inducible factor-2α/vascular endothelial growth factor to antagonize injury in hypoxia-stimulated cardiac microvascular endothelial cells.

Authors:  Yan-Ning Li; Xiu-Juan Wang; Bin Li; Kun Liu; Jin-Sheng Qi; Bing-Hui Liu; Ye Tian
Journal:  Chin Med J (Engl)       Date:  2015-04-20       Impact factor: 2.628

7.  Effect of Tongxinluo on Nephrin Expression via Inhibition of Notch1/Snail Pathway in Diabetic Rats.

Authors:  Fangqiang Cui; Dawei Zou; Yanbin Gao; Na Zhang; Jinyang Wang; Liping Xu; Jianguo Geng; Jiaoyang Li; Shengnan Zhou; Xinyao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-31       Impact factor: 2.629

8.  Tongxinluo Improves Cardiac Function and Ameliorates Ventricular Remodeling in Mice Model of Myocardial Infarction through Enhancing Angiogenesis.

Authors:  Wen-Wu Bai; Yi-Fan Xing; Bo Wang; Xiao-Ting Lu; Ying-Bin Wang; Yuan-Yuan Sun; Xiao-Qiong Liu; Tao Guo; Yu-Xia Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-27       Impact factor: 2.629

9.  Chinese patent medicine tongxinluo capsule for hypertension: a systematic review of randomised controlled trials.

Authors:  Jie Wang; Xingjiang Xiong; Wei Liu
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-17       Impact factor: 2.629

10.  Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation.

Authors:  Bo Wang; Qing Yang; Wen-wu Bai; Yi-fan Xing; Xiao-ting Lu; Yuan-yuan Sun; Yu-xia Zhao
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.